Record Q3 net income of $1.34 billion, up 8% year-on-year Year-to-date net income of $3.99 billion, up 10% on 2024…
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical…
Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor…
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025…
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~…
Highest-ever quarterly net income of $1.385 billion, up 16% YoY, reflects the Company's strong performance Board approves interim dividend of…
July 13, 2025 17:45 ET | Source: Crinetics Pharmaceuticals, Inc. Data show that PALSONIFY was well tolerated and IGF-1 levels…
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused…